MedTrace Logo

Study of Pharmacotherapy of Psychotic Depression

NCT00056472 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 259

Last updated 2013-08-02

Study results available
· View outcomes & findings →

Summary

This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.

Conditions

  • Major Depressive Disorder With Psychotic Features

Interventions

DRUG

Olanzapine

10-20mg/day

DRUG

Sertraline

150-200mg/day

OTHER

placebo

tablet that ressembles sertraline but contains no medication

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Barnett Meyers, MD · Cornell University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056472 on ClinicalTrials.gov